News Sentiment

HBIO sentiment intelligence

Harvard Bioscience Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Instruments & Supplies Read-through group
Latest close 6.14 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-0.2% over one week, +1.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Harvard Bioscience focuses on life science instruments as investors weigh long-term demand

Market Reaction

Balanced read

48/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -0.2% Price digesting
Trend fit Trend inactive 1.0% over four weeks
Fair value -71.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 34
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
TradingView 5
TradingKey 5
GlobeNewswire 4
simplywall.st 3
dars.gov.et 2
Moomoo 2
AD HOC NEWS 2

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 18
Analyst action 3
Macro sensitivity 1
Regulatory and legal 1
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-50 of 50
Stock Titan Direct company coverage

[10-Q] HARVARD BIOSCIENCE INC Quarterly Earnings Report

Harvard Bioscience (NASDAQ: HBIO) reported Q1 2026 revenue of $20.8 million, a 4.7% decrease year-over-year, mainly due to softened demand in academic and Asia-Pacific markets. Despite a narrower net loss of $3.4 million compared to the prior year's $50.3 million loss, the compan

Tone
Neutral 50/100
Event
Earnings
Published
12 May 2026 20:40
Source
Stock Titan
GuruFocus Direct company coverage

Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New Product Innovations

Harvard Bioscience Inc (HBIO) reported Q1 2026 revenue of $20.8 million, showing improved adjusted gross margin and growth driven by new product innovations such as MESH MEA, BTX, and SOHO telemetry products. Despite a slight revenue dip compared to Q1 2025 due to lower academic

Tone
Positive 67/100
Event
Earnings
Published
12 May 2026 19:40
Source
GuruFocus
Stock Titan Direct company coverage

Harvard Bioscience narrows quarterly loss as margins rise

Harvard Bioscience (HBIO) reported its Q1 2026 financial results, showing a narrowed net loss of $3.4 million compared to $50.3 million in Q1 2025, primarily due to a significant goodwill impairment in the prior year. While revenue dipped slightly to $20.8 million, the company sa

Tone
Negative 26/100
Event
Earnings
Published
12 May 2026 16:10
Source
Stock Titan